Lineage Cell Therapeutics’ (LCTX) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) in a report issued on Tuesday morning,Benzinga reports.

A number of other analysts have also recently weighed in on LCTX. B. Riley Financial raised their price objective on Lineage Cell Therapeutics from $3.00 to $4.00 and gave the stock a “buy” rating in a research report on Wednesday, March 25th. D. Boral Capital reaffirmed a “buy” rating and set a $3.00 target price on shares of Lineage Cell Therapeutics in a research report on Monday, May 4th. Finally, Canaccord Genuity Group started coverage on Lineage Cell Therapeutics in a research note on Tuesday, April 28th. They issued a “buy” rating and a $9.00 price target for the company. Four research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, Lineage Cell Therapeutics presently has an average rating of “Buy” and a consensus target price of $6.25.

Lineage Cell Therapeutics Stock Up 0.8%

NYSEAMERICAN LCTX opened at $1.22 on Tuesday. Lineage Cell Therapeutics has a 52 week low of $0.93 and a 52 week high of $2.09. The company has a 50 day moving average price of $1.28 and a 200 day moving average price of $1.52. The firm has a market cap of $304.15 million, a PE ratio of -4.21 and a beta of 1.51.

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) last announced its earnings results on Tuesday, May 12th. The company reported ($0.03) earnings per share for the quarter, missing the consensus estimate of ($0.02) by ($0.01). Lineage Cell Therapeutics had a negative net margin of 434.44% and a negative return on equity of 89.36%. The firm had revenue of $1.73 million during the quarter, compared to analyst estimates of $3.60 million. On average, equities research analysts anticipate that Lineage Cell Therapeutics will post -0.07 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Lineage Cell Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in LCTX. SG Americas Securities LLC purchased a new stake in shares of Lineage Cell Therapeutics during the fourth quarter valued at $25,000. Jump Financial LLC purchased a new stake in Lineage Cell Therapeutics during the 2nd quarter valued at about $28,000. DLD Asset Management LP acquired a new position in shares of Lineage Cell Therapeutics in the fourth quarter valued at about $33,000. Define Financial LLC purchased a new position in shares of Lineage Cell Therapeutics in the fourth quarter worth about $33,000. Finally, Qube Research & Technologies Ltd purchased a new position in shares of Lineage Cell Therapeutics in the second quarter worth about $35,000. 62.47% of the stock is currently owned by institutional investors and hedge funds.

About Lineage Cell Therapeutics

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel, allogeneic cell therapies built on pluripotent stem cell platforms. The company focuses on three primary therapeutic areas—retinal disease, neural repair and immune-effector cell oncology—leveraging its proprietary manufacturing processes to create off-the-shelf cell therapy candidates designed for broad patient populations.

Its lead candidate, OpRegen, comprises retinal pigment epithelium cells intended to slow or reverse vision loss in patients with geographic atrophy secondary to age-related macular degeneration.